Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Vyndaqel (Tafamidis) – Treatment for Transthyretin Familial Amyloid Polyneuropathy

Drug (Brand / Generic)

Vyndaqel (tafamidis)

Company / Licensee

Pfizer

Therapy Class

Nervous system drug

Product Description

Transthyretin stabiliser

Current Indication

Transthyretin Familial Amyloid Polyneuropathy

Market Sector

Genetic diseases

Development Status

Approved in Europe
Expand
Close
Close
Close

Go Top